European equities: no unified view in this week's published research.
One camp of analysts holds a neutral stance on eurozone stocks, pointing to slowing earnings momentum, higher energy prices, tighter monetary conditions and political risk as near-term headwinds. A separate thread of recent research frames Europe more constructively — not as a bet on better fundamentals, but as a possible destination if investors rotate away from US equities on the back of Washington political friction and a softer dollar. That case only works if the diversification flow actually shows up. The two views differ in framing more than they truly clash.
On single names, two stand out in the published work. On Vestas, one argument leans positive over the cyclical horizon, on the view that alternative energy returns to the policy agenda as Trump's leverage weakens. On Bayer, a technical read points to renewed upside: shares are said to have completed a three-wave correction from the July 2025 high near €53.92, with buyers re-emerging in October around the rising 200-day moving average. No timeframe was specified.